Display search results for ** instead (771 products)
30 Jun 2014  |  North America
The Ideal Life Sciences Hub
There are a number of factors that influence a life sciences companys decision in selecting the perfect location for its research and development (R&D), manufacturing operations, or headquarters. This Vital Signs article discusses those factors and discusses why Carlsbad, California, is one ideal Life Sciences hub location. Case studies include I...
USD 187.50 save 25 %
21 Mar 2014  |  North America
In early November 2013, Frost & Sullivan conducted an online survey, followed up by a live focus group with about 20 C-suite executives from leading commercial payer organizations across the US. The goal was to gain insights into how the health insurance industry is approaching the use of analytics solutions going into 2014. Analytics solutions we...
07 Apr 2014  |  North America
Healthcare systems across the globe are facing rising operation costs, shortage of skilled labor and budgetary restraints, which has resulted in reduction in efficiency and quality of care. An increasing aging population, need for chronic disease management and providing access to healthcare for the geographically fragmented population demands the ...
19 Dec 2014  |  North America
As the Wearables sector continues to explode in interest in the healthcare space in terms of potential hard benefit to consumers, providers, and vendors across the value chain of connected healthcare, areas are expanding in launches besides that of activity tracking. The following Vital Signs presents analyst discussion regarding brain wearables in...
31 Mar 2014  |  North America
This issue of Vital Signs, released on March 31, 2014, discusses the premium price tag of Gileads Sovaldi, Sonys genomic partnership with Illumina, and Craig Venters latest venture, Human Longevity, Inc.
30 Apr 2014  |  Global
This issue of Vital Signs, released on May 1, 2014, discusses the mega deals brewing in the pharma/biotech industry, Pfizer Incs Xalkori for non-small cell lung cancer, Novartis halt on RNAi development efforts, the high-ranked Malaysian healthcare system, Roches acquisition of IQuums Liat Analyzer, and Bio-Rads acquisition of GnuBio.
17 Jan 2014  |  North America
This issue of Vital Signs, released on January 17, 2014, discusses perspectives of different Frost & Sullivan analysts on recent noteworthy news items for our core markets including Pharma/Biotech, In Vitro Diagnostics, Advanced Medical Technology, and Connected Health.
28 Feb 2014  |  North America
This issue of Vital Signs, released on February 28, 2014, discusses three M&A transactions this month by Nestle, Myriad Genetics, and Fludigm and what these deals mean for the industry. Additionally, Illuminas first stab at personalized medicine through a partnership with Amgen is explored.
02 Jun 2014  |  Global
This issue of Vital Signs, released on June 2, 2014, discusses the latest strategy surrounding mega deals in the pharma/biotech industry, Eurofins agreement to acquire ViroCor-IBT Laboratories, Qiagens acquisition of BIOBASE, and the FDAs latest announcement on regulatory requirements for biosimilars.
01 Jul 2014  |  Global
This issue of Vital Signs, released on July 1, 2014, discusses the FDA approval of Biogens Eloctate, Qiagens acquisition of Primera Dx, Roches acquisition of Genia Technologies, Cues at-home connected lab test, and the Credihealth Teen Clinic.